Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qufengtong Pian is a traditional Chinese medicine (TCM) oral tablet developed by Guangxi Nanning Baihui Pharmaceutical Group. It is specifically categorized as a 'Zhuang medicine,' reflecting the ethnic medicinal traditions of the Guangxi region in China. The drug was developed as a national new drug and is indicated for the treatment of rheumatic conditions, including joint pain, limb numbness, and restricted movement caused by 'wind-dampness.' The herbal formula typically includes ingredients such as *Erythrinae Cortex* (Haitongpi), *Piperis Kadsurae Caulis* (Haifengteng), *Spatholobi Caulis* (Jixueteng), *Lonicerae Japonicae Caulis* (Rendongteng), and *Clematidis Radix et Rhizoma* (Weilingxian). These components work synergistically to expel wind, remove dampness, and promote blood circulation in the collaterals to provide analgesic and anti-inflammatory effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qufengtong Pian.